Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by TechnicalBuyon Sep 15, 2012 10:02am
258 Views
Post# 20366809

RE: Good article on recent VEGF trials by Eyelea

RE: Good article on recent VEGF trials by Eyelea

Don't' forget to compare ICO-007 to treatments mentioned in the previous article. Data form ICO's phase I study (https://www.icotherapeutics.com/_resources/Retina_Society_2010_David_Boyer.pdf) showed that more than 20% of patients had visual acuity improvement by over 5 letters. These patients failed all previous treatments by different therapies. So all therapies that you read in the previous article laser, vegf, steroids were ineffective at treating ICO's phase I patients.

Think about that. If ICO was able to have a significant impact on 20% of DME patients that no other therapy could treat, imagine what the outcome of ICO's therapy will be on patients who were responsive to previous therapies. I think it is reasonable to expect vast improvements in visual acuity of ico-007 in comparison to Lucentis.

TB.
technicalbuy.com

Bullboard Posts